A research lately revealed within the journal Aging Cell discovered that administering rilmenidine, a medicine used to deal with hypertension, to animals at each younger and older ages will increase lifespan and enhances total well being markers, much like the results of caloric restriction.
Researchers have found that the hypertension drug rilmenidine can lengthen lifespan and gradual getting old.
New analysis findings, revealed on January 20 within the journal Aging Cell, present that animals handled with rilmenidine, presently used to deal with hypertension (hypertension), at younger and older ages enhance lifespan and enhance well being markers, mimicking the results of caloric restriction. Rilmenidine, which is a prescription treatment, is marketed underneath the model names Albarel, Hyperium, Iterium, and Tenaxum.
They additionally display that the healthspan and lifespan advantages of rilmenidine remedy within the roundworm C. elegans are mediated by the I1-imidazoline receptor nish-1, figuring out this receptor as a possible longevity goal.
Unlike different medicine beforehand studied for this goal by the researchers, the widely-prescribed, oral antihypertensive rilmenidine has the potential for future translatability to people as unintended effects are uncommon and non-severe.
To date, a caloric restriction weight loss program has been thought-about essentially the most sturdy anti-aging intervention, selling longevity throughout species. However, studies of caloric restriction in humans have had mixed results and side effects, meaning finding medications like rilmenidine that can mimic the benefits of caloric restriction is the most reasonable anti-aging strategy.
Professor João Pedro Magalhães, who led the research whilst at the University of Liverpool and is now based at the University of Birmingham, said: “With a global aging population, the benefits of delaying aging, even if slightly, are immense. Repurposing drugs capable of extending lifespan and healthspan has a huge untapped potential in translational geroscience. For the first time, we have been able to show in animals that rilmenidine can increase lifespan. We are now keen to explore if rilmenidine may have other clinical applications.”
Reference: “Rilmenidine extends lifespan and healthspan in Caenorhabditis elegans via a nischarin I1-imidazoline receptor” by Dominic F. Bennett, Anita Goyala, Cyril Statzer, Charles W. Beckett, Alexander Tyshkovskiy, Vadim N. Gladyshev, Collin Y. Ewald and João Pedro de Magalhães, 20 January 2023, Aging Cell.
DOI: 10.1111/acel.13774
This study was undertaken by researchers from the University of Liverpool, ETH Zürich, and Harvard Medical School, and funded by the Swiss National Science Foundation, LongeCity, and the Biotechnology and Biological Sciences Research Council.
